Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lepirudin in Recurrent Small Cell Lung Cancer
NCT00003726Phase 2Terminated
- Sponsor
- Dartmouth Health
- Start
- Nov 1998
- Primary completion
- Jul 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lepirudin in small cell lung cancer (SCLC), sponsored by Dartmouth Health. Primary endpoints: Maximum Tolerated Dose at 18 months, Safety and Side Effects at 18 months and 1 more. Started Nov 1998; status: terminated.
02
Drugs
lepirudin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00003726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003726.